Amryt Pharma new drug application won’t go through advisory committee


Amryt Pharma PLC (NASDAQ:AMYT LON:AMYT) said the US Food and Drug Administration had confirmed its New Drug Application (NDA) for Oleogel-S10 does not require an Advisory Committee meeting.  

Oleogel-S10 was developed to treat junctional and dystrophic epidermolysis bullosa (EB), where the skin is fragile to even the lightest touch.

It is a rare condition that affects young children and adults and there is currently no approved treatment.

An FDA advisory committee is an independent body that gives direction to the agency over a product applying for approval.

Usually, though not always, the FDA acts on the recommendation of an advisory panel.

Amryt said last week it expects a decision on Oleogel-S10 on or before 30 November 2021.

Shares in Amryt rose 0.6% to 171p.


Please enter your comment!
Please enter your name here